Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sinclair

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Journal of Lipid Research|May 12, 2010
Biochemical characterization of cholesteryl ester transfer protein inhibitorsMollie Ranalletta, Kathleen K Bierilo, Ying Chen, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2016
Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonistsAnthony K Ogawa, Ellen Vande Bunte, Rudrajit Mal, et al.
The Lancet. Neurology|October 23, 2021
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trialPatrick Gavin Kehoe, Nicholas Turner, Beth Howden, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Journal of Lipid Research|May 12, 2010
Biochemical characterization of cholesteryl ester transfer protein inhibitorsMollie Ranalletta, Kathleen K Bierilo, Ying Chen, et al.
Bioorganic & Medicinal Chemistry Letters|May 11, 2016
Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonistsAnthony K Ogawa, Ellen Vande Bunte, Rudrajit Mal, et al.
The Lancet. Neurology|October 23, 2021
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trialPatrick Gavin Kehoe, Nicholas Turner, Beth Howden, et al.
Pageof 3